Hope on the Horizon for Triple-Negative Breast Cancer

Hope on the Horizon for Triple-Negative Breast Cancer

Not a member of My prIME? Join now for instant access.

Meeting Overview

An interactive poster gallery walk, featuring key presentations in triple-negative breast cancer, will provide a background for the live symposium. Faculty will be available to answer questions and discuss the data. The symposium presentations will follow and will begin with an illustrative case to set the stage for the discussion of current treatment strategies, clinical trial options, and individualized approaches to treatment.

Date and Location

Thursday, December 7, 2017
7.30 PM – 10.00 PM

Grand Ballroom, Salons E-F
Marriott Rivercenter
101 Bowie Street
San Antonio, Texas 78205



Thursday, December 7, 2017
7.30 PM – 10.00 PM



San Antonio, Texas, United States



1.75 AMA PRA Category 1 Credits

7.30 PM Registration, poster viewing, and dinner
8.15 PM Welcome, introduction, and triple-negative breast cancer (TNBC) quiz
Robert Coleman, MD, FRCP, FRCPE
8.23 PM Current treatment approaches: How I manage my patients
Harold J. Burstein, MD, PhD
8.35 PM Getting to grips with biology of TNBC
Jorge Reis-Filho, MD, PhD
8.50 PM Interactive faculty discussion and questions
8.55 PM Aim at the heart: The opportunities provided by antibody-drug conjugates and
targeted therapies in TNBC
Joyce O’Shaughnessey, MD
9.10 PM Interactive faculty discussion and questions
9.15 PM PARP inhibition in TNBC: Who, how, and when?
Andrew Tutt, MD, PhD
9.30 PM Interactive faculty discussion and questions
9.35 PM Immunotherapy for TNBC: Hope or hype?
Giuseppe Curigliano, MD, PhD
9.45 PM Interactive faculty discussion and questions
9.50 PM Summing it all up: prIME Points™
Robert Coleman, MD, FRCP, FRCPE
10.00 PM Adjourn


  • Robert Coleman, MD, FRCP, FRCPEMedical Director, prIME Oncology
    University of Sheffield
    Weston Park Hospital
    Sheffield, United Kingdom
  • Faculty

  • Harold J. Burstein, MD, PhDDana-Farber Cancer Institute
    Boston, Massachusetts, United States
  • Giuseppe Curigliano, MD, PhDEuropean Institute of Oncology
    University of Milan
    Milan, Italy
  • Joyce O’Shaughnessy, MDBaylor University Medical Center
    Texas Oncology
    US Oncology
    Dallas, Texas, United States
  • Jorge S. Reis-Filho, MD, PhD, FRCPathMemorial Sloan Kettering Cancer Center
    New York, New York, United States
  • Andrew Tutt, MD, PhDInstitute of Cancer Research
    London, United Kingdom

This educational activity is specifically designed for all attendees of the 2017 San Antonio Breast Cancer Symposium, as well as medical oncologists and other healthcare professionals who treat and manage patients with breast cancer.

After successful completion of this educational activity, participants should be able to:

  • Assess current and emerging clinical trial information concerning the use of investigational therapeutic approaches to care for patients with TNBC
  • Select the most appropriate treatment based upon patient and disease characteristics

This educational activity is supported by grants from AstraZeneca; Merck and Co, Inc.; and TESARO, Inc.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

prIME Oncology designates this live activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity is provided by prIME Oncology.

Sunshine Act

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.


Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.